DR. ELIZABETH STONER, M.D.
Medical Practice at Dudley Ave, Westfield, NJ
License number
New Jersey 136633
Category
Medical Practice
Type
Pediatrics
Address
Address
215 E Dudley Ave, Westfield, NJ 07090
Phone
(908) 881-6276
(908) 654-6276 (Fax)
(908) 654-6276 (Fax)
Professional information
Dr. Elizabeth Stoner, Westfield NJ - MD (Doctor of Medicine)
Specialties:
Pediatric Endocrinology
Address:
215 E Dudley Ave, Westfield 07090
(908) 654-6276 (Fax)
(908) 654-6276 (Fax)
Certifications:
Pediatric Endocrinology, 1983, Pediatrics, 1982
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Albert Einstein College of Medicine of Yeshiva University
Graduated: 1977
Jacobi-Einstein
Ny Hosp
Albert Einstein College of Medicine of Yeshiva University
Graduated: 1977
Jacobi-Einstein
Ny Hosp
Method Of Prevention Of Prostatic Carcinoma With 17-N-Monosubstituted-Carbamoyl-4-Aza-5-Androst-1-En-3-Ones
US Patent:
6432971, Aug 13, 2002
Filed:
Jun 6, 2001
Appl. No.:
09/875381
Inventors:
Glenn J. Gormley - Westfield NJ
Elizabeth Stoner - Westfield NJ
Elizabeth Stoner - Westfield NJ
Assignee:
Merck Co., Inc. - Rahway NJ
International Classification:
A61K 3144
US Classification:
514284
Abstract:
17-N-monosubstituted-carbamoyl-4-aza-5-androst-1-en-3-ones of the formula wherein R is selected from hydrogen, methyl and ethyl and R is a straight or branched chain alkyl, cycloalkyl, aralkyl of from 1-12 carbons, or monocyclic aryl optionally containing 1 or more lower alkyl substituents of 1-2 carbon atoms and/or 1 or more halogens, and Râ², Râ³, Râ²â³ are hydrogen or methyl are useful for the prevention of prostatic carcinoma.
Method Of Synergistic Treatment For Benign Prostatic Hyperplasia
US Patent:
6046183, Apr 4, 2000
Filed:
Feb 20, 1998
Appl. No.:
9/027105
Inventors:
Glenn J. Gormley - Westfield NJ
Elizabeth Stoner - Westfield NJ
Elizabeth Stoner - Westfield NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 3156, A61K 3158, A61K 31505
US Classification:
514170
Abstract:
Disclosed is an improved treatment for men with benign prostatic hyperplasia (BPH), involving combination therapy of a 5. alpha. -reductase inhibitor, e. g. a 17. beta. -substituted 4-azasteroid, a 17. beta. -substituted non-azasteroid, 17. beta. -acyl-3-carboxy-androst-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an. alpha. sub. 1 -adrenergic receptor blocker, i. e. , terazosin. The combination provides therapy at the molecular level for the underlying cause of the disease as well as providing symptomatic relief. Pharmaceutical compositions useful for treatment are also disclosed.
Method Of Treatment For Benign Prostatic Hyperplasia
US Patent:
5753641, May 19, 1998
Filed:
Apr 25, 1995
Appl. No.:
8/428595
Inventors:
Glenn J. Gormley - Westfield NJ
Elizabeth Stoner - Westfield NJ
Elizabeth Stoner - Westfield NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 3156, A61K 31495
US Classification:
514179
Abstract:
Disclosed is an improved treatment for men with benign prostatic hyperplasia (BPH), involving combination therapy of a 5. alpha. -reductase inhibitor, e. g. a 17. beta. -substituted 4-azasteroid, a 17. beta. -substituted non-azasteroid, 17. beta. -acyl-3-carboxy-androst-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an. alpha. sub. 1 -adrenergic receptor blocker, i. e. , terazosin. The combination provides therapy at the molecular level for the underlying cause of the disease as well as providing symptomatic relief. Pharmaceutical compositions useful for treatment are also disclosed.
Method Of Treatment Of Chronic Prostatitis With 17.Beta.-N-Monosubstituted-Carbamoyl-4-Aza-5.Alpha.-Androst-1-En-3-Ones
US Patent:
5629318, May 13, 1997
Filed:
Jun 2, 1995
Appl. No.:
8/448451
Inventors:
Glenn J. Gormley - Westfield NJ
Elizabeth Stoner - Westfield NJ
Elizabeth Stoner - Westfield NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 3144
US Classification:
514284
Abstract:
The present invention is concerned with the use of 17. beta. -N-monosubstituted-carbamaoyl-4-aza-5. alpha. -androst-1-en-3-one compounds as testosterone-5. alpha. -reductase inhibitors for the treatment of chronic prostatitis.
Method Of Treatment For Prostatic Cancer
US Patent:
5994362, Nov 30, 1999
Filed:
Jun 2, 1995
Appl. No.:
8/459063
Inventors:
Glenn J. Gormley - Westfield NJ
Elizabeth Stoner - Westfield NJ
Elizabeth Stoner - Westfield NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 3144, A61K 31275
US Classification:
514284
Abstract:
Disclosed is a new treatment for men with prostatic cancer involving combination therapy of a 5. alpha. -reductase inhibitor, i. e. , a 17. beta. -substituted 4-azasteroid, a 17. beta. -substituted non-azasteroid, 17. beta. -acyl-3-carboxyandrost-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylamino-phenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an antiandrogen, i. e. flutamide. Pharmaceutical compositions useful for treatment are also disclosed.
Method Of Determining And Reducing The Risk Of Bph-Related Urologic Events
US Patent:
2003006, Apr 10, 2003
Filed:
Sep 2, 1999
Appl. No.:
09/388658
Inventors:
ELIZABETH STONER - WESTFIELD NJ, US
DANIEL Z. WANG - EDISON NJ, US
JOANNE WALDSTREICHER - SCOTCH PLAINS NJ, US
DANIEL Z. WANG - EDISON NJ, US
JOANNE WALDSTREICHER - SCOTCH PLAINS NJ, US
International Classification:
A61K031/473, C07D221/18, G01N033/53
US Classification:
514/284000, 546/077000
Abstract:
This invention is concerned with a method of determining the risk of a urologic event, particularly an event selected from BPH-related surgery and acute urinary retention in a man by measuring the man's serum PSA level. The present invention also provides for a method of reducing the risk of the urologic event in a man determined to be at risk by the present urologic event risk-determining method by administration to the man of a compound which inhibits 5-reductase. Also provided is a kit for determining the risk of a urologic event.
Method Of Treating Androgenic Alopecia With 5.Alpha.-Reductase Inhibitors
US Patent:
5981543, Nov 9, 1999
Filed:
Jun 22, 1998
Appl. No.:
9/102454
Inventors:
Glenn J. Gormley - Westfield NJ
Keith D. Kaufman - Westfield NJ
Elizabeth Stoner - Westfield NJ
Joanne Waldstreicher - Scotch Plains NJ
Keith D. Kaufman - Westfield NJ
Elizabeth Stoner - Westfield NJ
Joanne Waldstreicher - Scotch Plains NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 3144, A61K 3158
US Classification:
514284
Abstract:
The instant invention involves a method of treating and/or reversing androgenic alopecia and promoting hair growth, and methods of treating acne vulgaris, seborrhea, and female hirsutism, by administering to a patient in need of such treatment a 5. alpha. -reductase 2 inhibitor such as finasteride, in a dosage amount under 5 mgs/day.
Transdermal Treatment With 5-Alpha Reductase Inhibitors
US Patent:
2002004, Apr 11, 2002
Filed:
Dec 7, 2001
Appl. No.:
10/010678
Inventors:
Glenn Gormley - Westfield NJ, US
Keith Kaufman - Westfield NJ, US
Elizabeth Stoner - Westfield NJ, US
Joanne Waldstreicher - Scotch Plains NJ, US
Keith Kaufman - Westfield NJ, US
Elizabeth Stoner - Westfield NJ, US
Joanne Waldstreicher - Scotch Plains NJ, US
International Classification:
A61K031/473, A61K007/06
US Classification:
514/290000, 424/070100
Abstract:
The instant invention involves a method of treating and/or reversing androgenic alopecia and promoting hair growth, and methods of treating acne vulgaris, seborrhea, and female hirsutism, by administering to a patient in need of such treatment a 5-reductase 2 inhibitor, such as finasteride, in a dosage amount under 5 mgs/day.
Method Of Treating Androgenic Alopecia With 5-.Alpha. Reductase Inhibitors
US Patent:
5547957, Aug 20, 1996
Filed:
Mar 17, 1994
Appl. No.:
8/214905
Inventors:
Glenn J. Gormley - Westfield NJ
Keith D. Kaufman - Westfield NJ
Elizabeth Stoner - Westfield NJ
Joanne Waldstreicher - Scotch Plains NJ
Keith D. Kaufman - Westfield NJ
Elizabeth Stoner - Westfield NJ
Joanne Waldstreicher - Scotch Plains NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 3158
US Classification:
514284
Abstract:
The instant invention involves a method of treating and/or reversing androgenic alopecia and promoting hair growth, and methods of treating acne vulgaris, seborrhea, and female hirsutism, by administering to a patient in need of such treatment a 5. alpha. -reductase 2 inhibitor, such as finasteride, in a dosage amount under 5 mgs/day.